Proactive Investors - Run By Investors For Investors

Ventripoint Diagnostics to bring its cardiac-imaging technology to France

France-based Irudigi will help bring to market Ventripoint's VMS+ device that uses AI to measure the whole heart with conventional ultrasound
heart
France's lack of MRI scanners heightens the need for Ventripoint’s technology

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCQB:VPTDF) on Wednesday announced it has signed an authorized sales agent agreement with Irudigi to bring its cardiac-imaging technology to France.

Irudigi, based in France, is a medical imaging and health-care information technology company. Under the sales agreement, Irudigi will help bring to market Ventripoint’s VMS+ device that uses artificial intelligence to streamline volumetric measurements of all four heart chambers with conventional ultrasound, according to a statement. 

“Irudigi's knowledge of the cardiac market in France and experience within the imaging industry will be an asset to the business as we continue to grow,” said Ventripoint CEO George Adams.

READ: Ventrioint Diagnostics to advance AI capabilities in its heart device with new gov't funding

Irudigi CEO Pierre Zavattero said that France lacks magnetic resonance imaging (MRI) scanners, which heightens the need for Ventripoint’s technology.

“There are over 1 million people suffering from cardiac impairments in France, a number that grew by 30% over the last decade,” he said. “The combination of low MRI coverage, a growing number of patients, and financial incentives make the Ventripoint VMS+ a perfectly suited solution for the French market.”

Ventripoint, based on Toronto, noted in its statement that neighbors Germany, Italy and Spain have at least twice as many MRIs than France. Consequently, current waiting times for MRIs are over a month in France, while they are only 1 to 2 weeks for echography, with a significantly shorter examination time, the company added.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

Pictured is the company's myLotus test
May 15 2019
Here we take a closer look at testing firm Concepta PLC (LON:CPT)
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
Sativa
June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use